Carlo A Marra

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3652714/publications.pdf Version: 2024-02-01

		36303	37204
269	11,616	51	96
papers	citations	h-index	g-index
272	272	272	15844
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Effects of a mobile phone short message service on antiretroviral treatment adherence in Kenya (WelTel Kenya1): a randomised trial. Lancet, The, 2010, 376, 1838-1845.	13.7	1,098
2	Meta-analysis of the Impact of 9 Medication Classes on Falls in Elderly Persons. Archives of Internal Medicine, 2009, 169, 1952.	3.8	1,016
3	Economic burden of asthma: a systematic review. BMC Pulmonary Medicine, 2009, 9, 24.	2.0	580
4	A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis. Social Science and Medicine, 2005, 60, 1571-1582.	3.8	333
5	Antibiotic Use in Children Is Associated With Increased Risk of Asthma. Pediatrics, 2009, 123, 1003-1010.	2.1	244
6	International comparison of cost of falls in older adults living in the community: a systematic review. Osteoporosis International, 2010, 21, 1295-1306.	3.1	236
7	The Economic Impact of Obstructive Sleep Apnea. Lung, 2008, 186, 7-12.	3.3	214
8	Evaluating Health-Related Quality-of-Life Studies in Paediatric Populations. Pharmacoeconomics, 2005, 23, 659-685.	3.3	209
9	The impact of obstructive sleep apnea and daytime sleepiness on work limitation. Sleep Medicine, 2007, 9, 42-53.	1.6	191
10	Does Antibiotic Exposure During Infancy Lead to Development of Asthma?. Chest, 2006, 129, 610-618.	0.8	185
11	Interferon-Based Combination Anti-Viral Therapy for Hepatitis C Virus After Liver Transplantation: A Review and Quantitative Analysis American Journal of Transplantation, 2006, 6, 1586-1599.	4.7	179
12	Does a home-based strength and balance programme in people aged >=80 years provide the best value for money to prevent falls? A systematic review of economic evaluations of falls prevention interventions. British Journal of Sports Medicine, 2010, 44, 80-89.	6.7	156
13	Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis. BMJ Open, 2019, 9, e022577.	1.9	144
14	Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis. Diabetologia, 2015, 58, 493-504.	6.3	140
15	Time-varying incidence of cancer after the onset of type 2 diabetes: evidence of potential detection bias. Diabetologia, 2011, 54, 2263-2271.	6.3	135
16	Cost-effectiveness of Continuous Positive Airway Pressure Therapy for Moderate to Severe Obstructive Sleep Apnea/Hypopnea. Archives of Internal Medicine, 2006, 166, 977.	3.8	131
17	The independent contribution of executive functions to health related quality of life in older women. BMC Geriatrics, 2010, 10, 16.	2.7	128
18	Measuring health-related quality of life in tuberculosis: a systematic review. Health and Quality of Life Outcomes, 2009, 7, 14.	2.4	125

#	Article	IF	CITATIONS
19	Direct Health Care Costs Associated with Asthma in British Columbia. Canadian Respiratory Journal, 2010, 17, 74-80.	1.6	122
20	A Comparison of Four Indirect Methods of Assessing Utility Values in Rheumatoid Arthritis. Medical Care, 2004, 42, 1125-1131.	2.4	114
21	Practical pharmacogenetics: the cost effectiveness of screening for thiopurine s-methyltransferase polymorphisms in patients with rheumatological conditions treated with azathioprine. Journal of Rheumatology, 2002, 29, 2507-12.	2.0	105
22	Physical activity as a mediator of the impact of chronic conditions on quality of life in older adults. Health and Quality of Life Outcomes, 2007, 5, 68.	2.4	92
23	Not all "quality-adjusted life years―are equal. Journal of Clinical Epidemiology, 2007, 60, 616-624.	5.0	89
24	5-HT3 receptor antagonistsvs traditional agents for the prophylaxis of postoperative nausea and vomiting. Canadian Journal of Anaesthesia, 2000, 47, 1008-1018.	1.6	88
25	Infliximab Treatment of Rheumatoid Arthritis and Crohn's Disease. Annals of Pharmacotherapy, 2003, 37, 1256-1265.	1.9	86
26	Treatment of Very Early Rheumatoid Arthritis With Symptomatic Therapy, Disease-Modifying Antirheumatic Drugs, or Biologic Agents. Annals of Internal Medicine, 2009, 151, 612.	3.9	86
27	Effectiveness and Cost Effectiveness of Human Papillomavirus Vaccine. Pharmacoeconomics, 2009, 27, 127-147.	3.3	82
28	Cost Analysis of an Adult Outpatient Parenteral Antibiotic Therapy (OPAT) Programme. Pharmacoeconomics, 2000, 18, 451-457.	3.3	79
29	Patient preferences and experiences of CPAP and oral appliances for the treatment of obstructive sleep apnea: a qualitative analysis. Sleep and Breathing, 2013, 17, 659-666.	1.7	77
30	Factors influencing quality of life in patients with active tuberculosis. Health and Quality of Life Outcomes, 2004, 2, 58.	2.4	76
31	Are indirect utility measures reliable and responsive in rheumatoid arthritis patients?. Quality of Life Research, 2005, 14, 1333-1344.	3.1	72
32	Health-Related Quality of Life Trajectories Among Adults With Tuberculosis. Chest, 2008, 133, 396-403.	0.8	70
33	Parental perceived value of a diagnosis for intellectual disability (ID): A qualitative comparison of families with and without a diagnosis for their child's ID. American Journal of Medical Genetics, Part A, 2009, 149A, 2393-2402.	1.2	69
34	Cost-effectiveness of self-managed versus physician-managed oral anticoagulation therapy. Cmaj, 2006, 174, 1847-1852.	2.0	68
35	Using the health assessment questionnaire to estimate preferenceâ€based single indices in patients with rheumatoid arthritis. Arthritis and Rheumatism, 2007, 57, 963-971.	6.7	68
36	An assessment of quality of sleep and the use of drugs with sedating properties in hospitalized adult patients. Health and Quality of Life Outcomes, 2004, 2, 17.	2.4	67

#	Article	IF	CITATIONS
37	The Cost Effectiveness of Human Papillomavirus Vaccines. Drugs, 2012, 72, 715-743.	10.9	67
38	Ten-Year Trends in Direct Costs of COPD. Chest, 2015, 148, 640-646.	0.8	66
39	An Overview of Economic Evaluations for Drugs Used in Rheumatoid Arthritis. Drugs, 2005, 65, 473-496.	10.9	65
40	Cost-Utility Analysis of Tissue Plasminogen Activator Therapy for Acute Ischaemic Stroke. Pharmacoeconomics, 2001, 19, 927-936.	3.3	64
41	The validity of generic and condition-specific preference-based instruments: the ability to discriminate asthma control status. Quality of Life Research, 2008, 17, 453-462.	3.1	64
42	The Effect of Smartphone Interventions on Patients With Chronic Obstructive Pulmonary Disease Exacerbations: A Systematic Review and Meta-Analysis. JMIR MHealth and UHealth, 2016, 4, e105.	3.7	63
43	Health State Utilities in Latent and Active Tuberculosis. Value in Health, 2008, 11, 1154-1161.	0.3	62
44	Bayesian and classical estimation of mixed logit: An application to genetic testing. Journal of Health Economics, 2009, 28, 598-610.	2.7	61
45	Trends in Asthma-Related Direct Medical Costs from 2002 to 2007 in British Columbia, Canada: A Population Based-Cohort Study. PLoS ONE, 2012, 7, e50949.	2.5	59
46	Cost-effectiveness of pharmacist care for managing hypertension in Canada. Canadian Pharmacists Journal, 2017, 150, 184-197.	0.8	59
47	Epidemiology and costs associated with genital warts in Canada. Sexually Transmitted Infections, 2008, 85, 111-115.	1.9	58
48	Preference-Based Quality of Life of End-Stage Ankle Arthritis Treated with Arthroplasty or Arthrodesis. Foot and Ankle International, 2010, 31, 563-566.	2.3	57
49	When patients have to pay a share of drug costs: effects on frequency of physician visits, hospital admissions and filling of prescriptions. Cmaj, 2005, 173, 1335-1340.	2.0	56
50	Value for Money? Array Genomic Hybridization for Diagnostic Testing for Genetic Causes of Intellectual Disability. American Journal of Human Genetics, 2010, 86, 765-772.	6.2	56
51	Cost-Effectiveness of Bronchial Thermoplasty, Omalizumab, and Standard Therapy for Moderate-to-Severe Allergic Asthma. PLoS ONE, 2016, 11, e0146003.	2.5	56
52	Meta-Analysis of Proton Pump Inhibitors in Treatment of Bleeding Peptic Ulcers. Annals of Pharmacotherapy, 2001, 35, 1528-1534.	1.9	55
53	Effect of an interactive text-messaging service on patient retention during the first year of HIV care in Kenya (WelTel Retain): an open-label, randomised parallel-group study. Lancet Public Health, The, 2018, 3, e143-e152.	10.0	54
54	Valuing the benefit of diagnostic testing for genetic causes of idiopathic developmental disability: willingness to pay from families of affected children. Clinical Genetics, 2009, 75, 514-521.	2.0	53

#	Article	IF	CITATIONS
55	The Scleroderma Patient-Centered Intervention Network Cohort: baseline clinical features and comparison with other large scleroderma cohorts. Rheumatology, 2018, 57, 1623-1631.	1.9	53
56	Quality-of-Life Assessment in an Outpatient Parenteral Antibiotic Program. Annals of Pharmacotherapy, 2002, 36, 1851-1855.	1.9	52
57	The impact of low family income on self-reported health outcomes in patients with rheumatoid arthritis within a publicly funded health-care environment $\hat{a}\in\hat{a}\in$ Presented in part as a poster at the International Society of Quality of Life Research Annual Meeting in Prague, Czech Republic, November 2003 Rheumatology. 2004. 43. 1390-1397.	1.9	52
58	A Metaâ€analysis of intradermal versus intramuscular influenza vaccines: Immunogenicity and Adverse Events. Influenza and Other Respiratory Viruses, 2013, 7, 584-603.	3.4	52
59	Pharmacistâ€initiated intervention trial in osteoarthritis: A multidisciplinary intervention for knee osteoarthritis. Arthritis Care and Research, 2012, 64, 1837-1845.	3.4	51
60	Cost-effectiveness of prophylactic dolasétron or droperidolvs rescue therapy in the prevention of PONV in ambulatory gynecologic surgery. Canadian Journal of Anaesthesia, 1999, 46, 536-543.	1.6	48
61	Cost Effectiveness of Herpes Zoster Vaccine in Canada. Pharmacoeconomics, 2009, 27, 991-1004.	3.3	48
62	Willingness to pay to assess patient preferences for therapy in a Canadian setting. BMC Health Services Research, 2005, 5, 43.	2.2	47
63	Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax, 2008, 63, 962-967.	5.6	47
64	Inhaled corticosteroids and the risk of lung cancer in COPD: a population-based cohort study. European Respiratory Journal, 2019, 53, 1801257.	6.7	46
65	In-Depth Analysis of Patient-Clinician Cell Phone Communication during the WelTel Kenya1 Antiretroviral Adherence Trial. PLoS ONE, 2012, 7, e46033.	2.5	46
66	The natural history of severe asthma and influences of early risk factors: a population-based cohort study. Thorax, 2016, 71, 267-275.	5.6	45
67	Comparison of HRQL Between Unicompartmental Knee Arthroplasty and Total Knee Arthroplasty for the Treatment of Osteoarthritis. Journal of Arthroplasty, 2013, 28, 187-190.	3.1	43
68	An Economic Evaluation of Resistance Training and Aerobic Training versus Balance and Toning Exercises in Older Adults with Mild Cognitive Impairment. PLoS ONE, 2013, 8, e63031.	2.5	43
69	Improving osteoarthritis detection in the community: Pharmacist identification of new, diagnostically confirmed osteoarthritis. Arthritis and Rheumatism, 2007, 57, 1238-1244.	6.7	41
70	Cost-Effectiveness of Continuous Positive Airway Pressure Therapy in Patients with Obstructive Sleep Apnea-Hypopnea in British Columbia. Canadian Respiratory Journal, 2008, 15, 159-165.	1.6	41
71	Does physical activity reduce seniors' need for healthcare?: a study of 24 281 Canadians. British Journal of Sports Medicine, 2010, 44, 902-904.	6.7	41
72	Risk of Breast Cancer After Onset of Type 2 Diabetes. Diabetes Care, 2011, 34, 2542-2544.	8.6	41

#	Article	IF	CITATIONS
73	The effect of weekly short message service communication on patient retention in care in the first year after HIV diagnosis: study protocol for a randomised controlled trial (WelTel Retain). BMJ Open, 2013, 3, e003155.	1.9	40
74	Identifying relationships between the professional culture of pharmacy, pharmacists' personality traits, and the provision of advanced pharmacy services. Research in Social and Administrative Pharmacy, 2016, 12, 56-67.	3.0	38
75	Evaluating societal preferences for human papillomavirus vaccine and cervical smear test screening programme. Sexually Transmitted Infections, 2011, 87, 52-57.	1.9	37
76	Cost-effectiveness of oral appliances in the treatment of obstructive sleep apnoea–hypopnoea. Sleep and Breathing, 2009, 13, 241-252.	1.7	36
77	A statistical method was used for the meta-analysis of tests for latent TBÂin the absence of a gold standard, combining random-effect andÂlatent-class methods to estimate test accuracy. Journal of Clinical Epidemiology, 2010, 63, 257-269.	5.0	36
78	Societal preferences for rheumatoid arthritis treatments: evidence from a discrete choice experiment. Rheumatology, 2015, 54, 1816-1825.	1.9	35
79	Meta-Analysis of Basiliximab for Immunoprophylaxis in Renal Transplantation. BioDrugs, 2003, 17, 271-279.	4.6	34
80	A valuation of patients' willingness-to-pay for insulin delivery in diabetes. International Journal of Technology Assessment in Health Care, 2009, 25, 359-366.	0.5	34
81	Agreement between aggregate and individual-level measures of income and education: a comparison across three patient groups. BMC Health Services Research, 2011, 11, 69.	2.2	34
82	Barriers to integrating personalized medicine into clinical practice: a best–worst scaling choice experiment. Genetics in Medicine, 2012, 14, 520-526.	2.4	34
83	Economic and Humanistic Burden of External Genital Warts. Pharmacoeconomics, 2012, 30, 1-16.	3.3	34
84	Factors associated with pharmacists' perceptions of their working conditions and safety and effectiveness of patient care. Canadian Pharmacists Journal, 2016, 149, 18-27.	0.8	34
85	Economic evaluation of dose–response resistance training in older women: a cost-effectiveness and cost-utility analysis. Osteoporosis International, 2011, 22, 1355-1366.	3.1	33
86	Excess medical costs in patients with asthma and the role of comorbidity. European Respiratory Journal, 2016, 48, 1584-1592.	6.7	33
87	A discrete choice experiment evaluation of patients' preferences for different risk, benefit, and delivery attributes of insulin therapy for diabetes management. Patient Preference and Adherence, 2010, 4, 433.	1.8	32
88	Future Impact of Various Interventions on the Burden of COPD in Canada: A Dynamic Population Model. PLoS ONE, 2012, 7, e46746.	2.5	32
89	Systematic Review of the Treatment of Early Lyme Disease. Drugs, 1999, 57, 157-173.	10.9	31
90	Barriers for integrating personalized medicine into clinical practice: A qualitative analysis. American Journal of Medical Genetics, Part A, 2013, 161, 758-763.	1.2	31

#	Article	lF	CITATIONS
91	Validation of the Selfâ€Efficacy for Managing Chronic Disease Scale: A Scleroderma Patientâ€Centered Intervention Network Cohort Study. Arthritis Care and Research, 2016, 68, 1195-1200.	3.4	31
92	Economic evaluation of mobile phone text message interventions to improve adherence to HIV therapy in Kenya. Medicine (United States), 2017, 96, e6078.	1.0	31
93	Cost-Effectiveness of Using a Molecular Diagnostic Test to Improve Preoperative Diagnosis of Thyroid Cancer. Value in Health, 2012, 15, 1005-1013.	0.3	30
94	Quantitative analysis of multiple sclerosis patients' preferences for drug treatment: a best–worst scaling study. Therapeutic Advances in Neurological Disorders, 2016, 9, 287-296.	3.5	29
95	Levofloxacin Treatment of Active Tuberculosis and the Risk of Adverse Events. Chest, 2005, 128, 1406-1413.	0.8	28
96	Do visual analogue scale (VAS) derived standard gamble (SG) utilities agree with Health Utilities Index utilities? A comparison of patient and community preferences for health status in rheumatoid arthritis patients. Health and Quality of Life Outcomes, 2006, 4, 25.	2.4	28
97	Genomic testing to determine drug response: measuring preferences of the public and patients using Discrete Choice Experiment (DCE). BMC Health Services Research, 2013, 13, 454.	2.2	28
98	Pharmacy-based Immunization in Rural Communities Strategy (PhICS). Canadian Pharmacists Journal, 2014, 147, 33-44.	0.8	28
99	Socioeconomic Differences in Preferences and Willingness-to-Pay for Insulin Delivery Systems in Type 1 and Type 2 Diabetes. Diabetes Technology and Therapeutics, 2009, 11, 567-573.	4.4	27
100	After patients are diagnosed with knee osteoarthritis, what do they do?. Arthritis Care and Research, 2010, 62, 510-515.	3.4	27
101	Pharmacists' Preferences for Providing Patient-Centered Services: A Discrete Choice Experiment to Guide Health Policy. Annals of Pharmacotherapy, 2010, 44, 1554-1564.	1.9	27
102	Is the delay in diagnosis of pulmonary tuberculosis related to exposure to fluoroquinolones or any antibiotic?. International Journal of Tuberculosis and Lung Disease, 2011, 15, 1062-1068.	1.2	27
103	Is Surgical Fixation for Stress-Positive Unstable Ankle Fractures Cost Effective? Results of a Multicenter Randomized Control Trial. Journal of Orthopaedic Trauma, 2012, 26, 652-658.	1.4	27
104	Need for Speed: An Efficient Algorithm for Calculation of Single-Parameter Expected Value of Partial Perfect Information. Value in Health, 2013, 16, 438-448.	0.3	27
105	Action Seniors! - secondary falls prevention in community-dwelling senior fallers: study protocol for a randomized controlled trial. Trials, 2015, 16, 144.	1.6	27
106	Independent and inverse association of healthcare utilisation with physical activity in older adults with multiple chronic conditions. British Journal of Sports Medicine, 2010, 44, 1024-1028.	6.7	26
107	Patient Preference for Latent Tuberculosis Infection Preventive Treatment: A Discrete Choice Experiment. Value in Health, 2011, 14, 937-943.	0.3	26
108	Detection Bias and Overestimation of Bladder Cancer Risk in Type 2 Diabetes: A matched cohort study. Diabetes Care, 2013, 36, 3070-3075.	8.6	26

#	Article	IF	CITATIONS
109	The added effect of comorbidity on health-related quality of life in patients with asthma. Quality of Life Research, 2015, 24, 2507-2517.	3.1	26
110	The effectiveness and toxicity of cyclosporin A in rheumatoid arthritis: longitudinal analysis of a population-based registry. Arthritis and Rheumatism, 2001, 45, 240-245.	6.7	25
111	Cost-Effectiveness of the Addition of Rituximab to CHOP Chemotherapy in First-Line Treatment for Diffuse Large B-Cell Lymphoma in a Population-Based Observational Cohort in British Columbia, Canada. Value in Health, 2010, 13, 703-711.	0.3	25
112	Do inhaled corticosteroids protect against lung cancer in patients with COPD? A systematic review. Respirology, 2017, 22, 61-70.	2.3	25
113	Pharmacist prescribing and care improves cardiovascular risk, but is it cost-effective? A cost-effectiveness analysis of the R _x EACH study. Canadian Pharmacists Journal, 2019, 152, 257-266.	0.8	25
114	Health state utility values: A description of their development and application for rheumatic diseases. Arthritis and Rheumatism, 2008, 59, 1018-1026.	6.7	24
115	Sustained Cognitive and Economic Benefits of Resistance Training Among Community- Dwelling Senior Women: A 1-Year Follow-up Study of the Brain Power Study. Archives of Internal Medicine, 2010, 170, 2036.	3.8	24
116	The cost of fall related presentations to the ED: A prospective, in-person, patient-tracking analysis of health resource utilization. Osteoporosis International, 2012, 23, 1513-1519.	3.1	24
117	Does Introducing Imprecision around Probabilities for Benefit and Harm Influence the Way People Value Treatments?. Medical Decision Making, 2016, 36, 490-502.	2.4	24
118	SF-6D and EQ-5D result in widely divergent incremental cost-effectiveness ratios in a clinical trial of older women: implications for health policy decisions. Osteoporosis International, 2012, 23, 1849-1857.	3.1	23
119	Using Optimal Test Assembly Methods for Shortening Patientâ€Reported Outcome Measures: Development and Validation of the Cochin Hand Function Scaleâ€6: A Scleroderma Patientâ€Centered Intervention Network Cohort Study. Arthritis Care and Research, 2016, 68, 1704-1713.	3.4	23
120	Consumer preferences for food allergen labeling. Allergy, Asthma and Clinical Immunology, 2017, 13, 19.	2.0	23
121	Cost-Effectiveness Analysis of Enoxaparin versus Unfractionated Heparin for Acute Coronary Syndromes. Pharmacoeconomics, 1999, 16, 533-542.	3.3	22
122	A systematic review of economic evaluations of therapy in asthma. Journal of Asthma and Allergy, 2010, 3, 33.	3.4	22
123	Randomized Controlled Trial Evaluating Pictogram Augmentation of HIV Medication Information. Annals of Pharmacotherapy, 2011, 45, 1378-1383.	1.9	22
124	Challenges in Measuring the Societal Value of Orphan Drugs: Insights from a Canadian Stated Preference Survey. Patient, 2015, 8, 93-101.	2.7	22
125	Testing the External Validity of a Discrete Choice Experiment Method: An Application to Latent Tuberculosis Infection Treatment. Value in Health, 2017, 20, 969-975.	0.3	22
126	Risk of preterm delivery and small-for-gestational-age births in women with autoimmune disease using biologics before or during pregnancy: a population-based cohort study. Annals of the Rheumatic Diseases, 2018, 77, annrheumdis-2018-213023.	0.9	22

#	Article	IF	CITATIONS
127	Falls-related self-efficacy is independently associated with quality-adjusted life years in older women. Age and Ageing, 2011, 40, 340-346.	1.6	21
128	Deâ€escalation of therapy for pediatric medulloblastoma: Tradeâ€offs between quality of life and survival. Pediatric Blood and Cancer, 2014, 61, 1300-1304.	1.5	21
129	Costâ€Utility Analysis of a Multidisciplinary Strategy to Manage Osteoarthritis of the Knee: Economic Evaluation of a Cluster Randomized Controlled Trial Study. Arthritis Care and Research, 2014, 66, 810-816.	3.4	21
130	A philosophical framework for pharmacy in the 21st century guided by ethical principles. Research in Social and Administrative Pharmacy, 2018, 14, 309-316.	3.0	21
131	Performance Characteristics of Spirometry With Negative Bronchodilator Response and Methacholine Challenge Testing and Implications for Asthma Diagnosis. Chest, 2020, 158, 479-490.	0.8	21
132	Short-term influence of adalimumab on work productivity outcomes in patients with rheumatoid arthritis. Journal of Rheumatology, 2008, 35, 1729-36.	2.0	21
133	A New Ciprofloxacin Stepdown Program in the Treatment of High-Risk Febrile Neutropenia: A Clinical and Economic Analysis. Pharmacotherapy, 2000, 20, 931-940.	2.6	20
134	Impact of adverse drug reaction and predictivity of quality of life status in tuberculosis. European Respiratory Journal, 2010, 36, 206-208.	6.7	20
135	Introduction to economic modeling for clinical rheumatologists: application to biologic agents in rheumatoid arthritis. Clinical Rheumatology, 2011, 30, 9-18.	2.2	20
136	The validity of the SF-12 and SF-6D instruments in people living with HIV/AIDS in Kenya. Health and Quality of Life Outcomes, 2017, 15, 143.	2.4	20
137	Patients With Genital Warts Have a Decreased Quality of Life. Sexually Transmitted Diseases, 2009, 36, 258-260.	1.7	19
138	Comparative outcomes of leukotriene receptor antagonists and long-acting Î ² -agonists as add-on therapy in asthmatic patients: A population-based study. Journal of Allergy and Clinical Immunology, 2013, 132, 63-69.	2.9	19
139	The economics of treatment in early rheumatoid arthritis. Best Practice and Research in Clinical Rheumatology, 2009, 23, 83-92.	3.3	17
140	Effectiveness of a pharmacist-driven intervention in COPD (EPIC): study protocol for a randomized controlled trial. Trials, 2016, 17, 502.	1.6	17
141	The Impact of Price-cap Regulations on Exit by Generic Pharmaceutical Firms. Medical Care, 2016, 54, 884-890.	2.4	17
142	Validation of the Social Appearance Anxiety Scale in Patients With Systemic Sclerosis: A Scleroderma Patient entered Intervention Network Cohort Study. Arthritis Care and Research, 2018, 70, 1557-1562.	3.4	17
143	Costs and Health Outcomes Associated With Primary vs Secondary Care After an Asthma-Related Hospitalization. Chest, 2013, 144, 428-435.	0.8	16
144	Dispensation of long-acting agonists with or without inhaled corticosteroids, and risk of asthma-related hospitalisation: a population-based study. Thorax, 2014, 69, 328-334.	5.6	16

#	Article	IF	CITATIONS
145	Diagnostic Strategies Incorporating Computed Tomography Angiography for Pulmonary Embolism. Journal of Thoracic Imaging, 2014, 29, 209-216.	1.5	16
146	Ten-year trends in direct costs of asthma: a population-based study. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 291-299.	5.7	16
147	Evaluating Canadians' Values for Drug Coverage Decision Making. Value in Health, 2019, 22, 362-369.	0.3	16
148	Health economic evaluation: A primer for the practicing rheumatologist. Arthritis and Rheumatism, 2006, 55, 648-656.	6.7	15
149	Abatacept: A Novel Treatment for Moderate-to-Severe Rheumatoid Arthritis. Pharmacotherapy, 2007, 27, 1693-1701.	2.6	15
150	Cost-Effectiveness of LTBI Treatment for TB Contacts in British Columbia. Value in Health, 2008, 11, 842-852.	0.3	15
151	Reliability studies of diagnostic tests are not using enough observers for robust estimation of interobserver agreement: a simulation study. Journal of Clinical Epidemiology, 2008, 61, 722-727.	5.0	15
152	Empowering pharmacists in asthma management through interactive SMS (EmPhAsIS): study protocol for a randomized controlled trial. Trials, 2014, 15, 488.	1.6	15
153	Healthcare Worker Preferences for Active Tuberculosis Case Finding Programs in South Africa: A Best-Worst Scaling Choice Experiment. PLoS ONE, 2015, 10, e0133304.	2.5	15
154	Perceptions of British Columbia residents and their willingness to pay for medication management services provided by pharmacists. Canadian Pharmacists Journal, 2015, 148, 263-273.	0.8	15
155	Challenges with cost-utility analyses of behavioural interventions among older adults at risk for dementia. British Journal of Sports Medicine, 2015, 49, 1343-1347.	6.7	15
156	Economic Impact of Standardized Orders for Antimicrobial Prophylaxis Program. Annals of Pharmacotherapy, 2000, 34, 154-160.	1.9	14
157	Effects of prescription adaptation by pharmacists. BMC Health Services Research, 2010, 10, 313.	2.2	14
158	Antibiotic consumption in children prior to diagnosis of asthma. BMC Pulmonary Medicine, 2011, 11, 32.	2.0	14
159	Practice guidelines for pharmacists: The management of osteoarthritis. Canadian Pharmacists Journal, 2017, 150, 156-168.	0.8	14
160	Are patients willing to pay for total shoulder arthroplasty? Evidence from a discrete choice experiment. Canadian Journal of Surgery, 2016, 59, 107-112.	1.2	14
161	Perspectives of Patients with Multiple Sclerosis on Drug Treatment. International Journal of MS Care, 2018, 20, 269-277.	1.0	14
162	Continuous Positive Airway Pressure Therapy for Obstructive Sleep Apnea Syndrome: Do the Dollars Make Sense?. Sleep, 2005, 28, 1211-1213.	1.1	13

#	Article	IF	CITATIONS
163	Exploring patients' perceptions for insulin therapy in type 2 diabetes: a Brazilian and Canadian qualitative study. Patient Preference and Adherence, 2010, 4, 171.	1.8	13
164	Valuing Health for Clinical and Economic Decisions: Directions Relevant for Rheumatologists. Journal of Rheumatology, 2011, 38, 1770-1775.	2.0	13
165	BC Medication Management Project. Canadian Pharmacists Journal, 2015, 148, 90-100.	0.8	13
166	Statin use and lung cancer risk in chronic obstructive pulmonary disease patients: a population-based cohort study. Respiratory Research, 2020, 21, 118.	3.6	13
167	A quantitative evaluation of the regulatory assessment of the benefits and risks of rofecoxib relative to naproxen: an application of the incremental netâ€benefit framework. Pharmacoepidemiology and Drug Safety, 2010, 19, 1172-1180.	1.9	12
168	"Employment and arthritis: making it work―a randomized controlled trial evaluating an online program to help people with inflammatory arthritis maintain employment (study protocol). BMC Medical Informatics and Decision Making, 2014, 14, 59.	3.0	12
169	OMERACT Quality-adjusted Life-years (QALY) Working Group: Do Current QALY Measures Capture What Matters to Patients?. Journal of Rheumatology, 2017, 44, 1899-1903.	2.0	12
170	Tapering Biologic Therapy for Rheumatoid Arthritis: A Qualitative Study of Patient Perspectives. Patient, 2020, 13, 225-234.	2.7	12
171	Cost-Effectiveness Analysis of Abciximab: A Canadian Hospital Perspective. Annals of Pharmacotherapy, 1998, 32, 536-542.	1.9	11
172	Pharmacists' Perspectives on Providing Chronic Disease Management Services in the Community — Part I: Current Practice Environment. Canadian Pharmacists Journal, 2009, 142, 234-239.	0.8	11
173	Pharmacists' Perspectives on Providing Chronic Disease Management Services in the Community — Part II: Development and Implementation of Services. Canadian Pharmacists Journal, 2009, 142, 284-288.e1.	0.8	11
174	Sustained Economic Benefits of Resistance Training in Communityâ€Đwelling Senior Women. Journal of the American Geriatrics Society, 2011, 59, 1232-1237.	2.6	11
175	Health economic evaluation of plasma oxysterol screening in the diagnosis of Niemann–Pick Type C disease among intellectually disabled using discrete event simulation. Molecular Genetics and Metabolism, 2015, 114, 226-232.	1.1	11
176	Excess Productivity Costs of Systemic Lupus Erythematosus, Systemic Sclerosis, and Sjögren's Syndrome: A General Population–Based Study. Arthritis Care and Research, 2019, 71, 142-154.	3.4	11
177	A Cost-effectiveness Analysis of Pneumococcal Vaccination in Street-involved, HIV-infected Patients. Canadian Journal of Public Health, 2000, 91, 334-339.	2.3	10
178	An Ounce of Prevention Is Worth a Pound of Cure: A Cost-Effectiveness Analysis of Incidentally Detected Aneurysms in Functional MRI Research. Value in Health, 2010, 13, 761-769.	0.3	10
179	Network vs. Pairwise Meta-Analyses: A Case Study of the Impact of an Evidence-Synthesis Paradigm on Value of Information Outcomes. Pharmacoeconomics, 2014, 32, 995-1004.	3.3	10
180	Preferences for â€~New' Treatments Diminish in the Face of Ambiguity. Health Economics (United) Tj ETQq(000.rgBT	Overlock 10 ⁻

11

#	Article	IF	CITATIONS
181	Incremental direct medical costs of systemic lupus erythematosus patients in the years preceding diagnosis: A general population-based study. Lupus, 2018, 27, 1247-1258.	1.6	10
182	Capturing Adult Patient Preferences Toward Benefits and Risks of Second-Line Antihyperglycemic Medications Used in Type 2 Diabetes: A Discrete Choice Experiment. Canadian Journal of Diabetes, 2020, 44, 6-13.	0.8	10
183	The issue of comparators in economic evaluations of biologic response modifiers in rheumatoid arthritis. Best Practice and Research in Clinical Rheumatology, 2012, 26, 659-676.	3.3	9
184	A Quantitative Benefit-Risk Analysis of Isoniazid for Treatment of Latent Tuberculosis Infection Using Incremental Benefit Framework. Value in Health, 2013, 16, 66-75.	0.3	9
185	Exploring the Potential Cost-Effectiveness of Patient Decision Aids for Use in Adults with Obstructive Sleep Apnea. Medical Decision Making, 2015, 35, 671-682.	2.4	9
186	Cognitive status is a determinant of health resource utilization among individuals with a history of falls: a 12-month prospective cohort study. Osteoporosis International, 2016, 27, 943-951.	3.1	9
187	Tapering biologic therapy for people with rheumatoid arthritis in remission: A review of patient perspectives and associated clinical evidence. Musculoskeletal Care, 2019, 17, 161-169.	1.4	9
188	Feasibility of a randomised controlled trial of two types of written information for people with knee osteoarthritis. Osteoarthritis and Cartilage Open, 2022, 4, 100254.	2.0	9
189	Chlamydia trachomatis in Adolescents and Adults. Pharmacoeconomics, 1998, 13, 191-222.	3.3	8
190	An Economic Model of 2-Hour Post-Dose Ciclosporin Monitoring in Renal Transplantation. Pharmacoeconomics, 2004, 22, 621-632.	3.3	8
191	Approval process and access to prescription drugs in Canada. Arthritis and Rheumatism, 2006, 55, 9-11.	6.7	8
192	Assessing Pharmacists' Attitudes regarding Delivery of the Pandemic Influenza Vaccine in British Columbia. Canadian Pharmacists Journal, 2010, 143, 278-284.	0.8	8
193	TWOâ€LEVEL RESAMPLING AS A NOVEL METHOD FOR THE CALCULATION OF THE EXPECTED VALUE OF SAMPLE INFORMATION IN ECONOMIC TRIALS. Health Economics (United Kingdom), 2013, 22, 877-882.	1.7	8
194	Impact of allowing pharmacists to independently renew prescriptions: A population-based study. Journal of the American Pharmacists Association: JAPhA, 2015, 55, 398-404.	1.5	8
195	Group Medical Visits (GMVs) in primary care: an RCT of group-based versus individual appointments to reduce HbA1c in older people: Figure1. BMJ Open, 2015, 5, e007441.	1.9	8
196	Productivity Losses and Costs in the Less-Common Systemic Autoimmune Rheumatic Diseases. Current Rheumatology Reports, 2017, 19, 72.	4.7	8
197	Filling the gaps in SARDs research: collection and linkage of administrative health data and self-reported survey data for a general population-based cohort of individuals with and without diagnoses of systemic autoimmune rheumatic disease (SARDs) from British Columbia, Canada. BMJ Open. 2017. 7. e013977.	1.9	8
198	Reliability and Validity of Three Versions of the Brief Fear of Negative Evaluation Scale in Patients With Systemic Sclerosis: A Scleroderma Patientâ€Centered Intervention Network Cohort Study. Arthritis Care and Research, 2018, 70, 1646-1652.	3.4	8

#	Article	IF	CITATIONS
199	Exploring strategies to support medication adherence in patients with inflammatory arthritis: a patient-oriented qualitative study using an interactive focus group activity. Patient Preference and Adherence, 2018, Volume 12, 2015-2025.	1.8	8
200	Socioeconomic status at diagnosis influences the incremental direct medical costs of systemic lupus erythematosus: A longitudinal population-based study. Seminars in Arthritis and Rheumatism, 2020, 50, 77-83.	3.4	8
201	What free services do pharmacists offer? Investigating the provision of unfunded pharmacy services in community pharmacies. Research in Social and Administrative Pharmacy, 2021, 17, 588-594.	3.0	8
202	Cost-Minimization Analysis of Piperacillin/Tazobactam versus Imipenem/Cilastatin for the Treatment of Serious Infections: A Canadian Hospital Perspective. Annals of Pharmacotherapy, 1999, 33, 156-162.	1.9	7
203	A Case for Rimantadine to Be Marketed in Canada for Prophylaxis of Influenza a Virus Infection. Canadian Respiratory Journal, 2003, 10, 381-388.	1.6	7
204	The Cost of Sleep Disorders: No Snoring Matter. Sleep, 2006, 29, 282-283.	1.1	7
205	Rheumatoid arthritis: A primer for pharmacists. American Journal of Health-System Pharmacy, 2006, 63, S4-S10.	1.0	7
206	Family Physicians' Perceptions of Pharmacy Adaptation Services in British Columbia. Canadian Pharmacists Journal, 2011, 144, 172-178.	0.8	7
207	The Demise of Portable Monitoring to Diagnose OSA? Not So Fast!. Sleep, 2011, 34, 691-692.	1.1	7
208	Practical strategies and perceptions from community pharmacists following their experiences with conducting pharmacy practice research: a qualitative content analysis. International Journal of Pharmacy Practice, 2018, 26, 302-309.	0.6	7
209	Characterization of pharmacist-based medication management services in a community pharmacy. Research in Social and Administrative Pharmacy, 2020, 16, 178-182.	3.0	7
210	Technical Note: Acceptability Curves Could Be Misleading When Correlated Strategies Are Compared. Medical Decision Making, 2008, 28, 306-307.	2.4	6
211	Evaluating the Labour Costs Associated with Pharmacy Adaptation Services in British Columbia. Canadian Pharmacists Journal, 2012, 145, 78-82.	0.8	6
212	Economic Evaluation of Pharmacists Tackling the Burden of Hypertension in Japan. Hypertension, 2019, 74, e54-e55.	2.7	6
213	Pharmacists' perceptions of their working conditions and the factors influencing this: Results from 5 Canadian provinces. Canadian Pharmacists Journal, 2020, 153, 161-169.	0.8	6
214	R _x IALTA: evaluating the effect of a pharmacist-led intervention on CV risk in patients with chronic inflammatory diseases in a community pharmacy setting: a prospective pre–post intervention study. BMJ Open, 2021, 11, e043612.	1.9	6
215	Canadian Policy on Food Allergen Labelling: Consumers' Perspectives Regarding Unmet Needs. Universal Journal of Public Health, 2015, 3, 41-48.	0.1	6
216	Considerations and preliminary proposals for defining a reference case for economic evaluations in ankylosing spondylitis. Journal of Rheumatology, 2007, 34, 1178-83.	2.0	6

#	Article	IF	CITATIONS
217	Pharmacy Owner and Manager Perceptions of Pharmacy Adaptation Services in British Columbia. Canadian Pharmacists Journal, 2011, 144, 231-235.	0.8	5
218	Incorporating external evidence in trial-based cost-effectiveness analyses: the use of resampling methods. Trials, 2014, 15, 201.	1.6	5
219	Populationâ€based evaluation of the effectiveness of two regimens for emergency contraception. International Journal of Gynecology and Obstetrics, 2016, 133, 342-346.	2.3	5
220	Pharmacists of the future: What determines graduates' desire to engage in patient-centred services?. Research in Social and Administrative Pharmacy, 2021, 17, 545-552.	3.0	5
221	Patient reported outcomes for rheumatoid arthritis: where are we and where are we going?. Journal of Rheumatology, 2008, 35, 1482-3.	2.0	5
222	Cost Effectiveness Analysis of Azithromycin and Doxycycline forChlamydia TrachomatisInfection in Women: A Canadian Perspective. Canadian Journal of Infectious Diseases & Medical Microbiology, 1997, 8, 202-208.	0.3	4
223	Cost–effectiveness of tumor necrosis factor-α antagonists in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Expert Review of Pharmacoeconomics and Outcomes Research, 2007, 7, 155-169.	1.4	4
224	Now that we know what's BeSt, what is good value for the money?. Arthritis and Rheumatism, 2009, 61, 289-290.	6.7	4
225	Responses to Comments of Weis. Health and Quality of Life Outcomes, 2010, 8, 6.	2.4	4
226	Risk of Gastrointestinal Events in Patients with Rheumatoid Arthritis After Withdrawal of Rofecoxib. Journal of Rheumatology, 2012, 39, 910-915.	2.0	4
227	Tuberculosis testing for healthcare workers in South Africa: A health service analysis using Porter's Five Forces Framework. International Journal of Healthcare Management, 2017, 10, 49-56.	2.0	4
228	Societal preferences in the treatment of pediatric medulloblastoma: Balancing risk of death and quality of life. Pediatric Blood and Cancer, 2017, 64, e26340.	1.5	4
229	Adaptation of POCT for pharmacies to reduce risk and optimize access to care in HIV, the APPROACH study protocol: examining acceptability and feasibility. Pilot and Feasibility Studies, 2018, 4, 59.	1.2	4
230	Identifying Community Pharmacist Preferences For Prescribing Services in Primary Care in New Zealand: A Discrete Choice Experiment. Applied Health Economics and Health Policy, 2021, 19, 253-266.	2.1	4
231	Design of a randomized trial of a multidisciplinary intervention for knee osteoarthritis: Pharmacist Initiated Intervention Trial in Osteoarthritis (PhIT-OA). Canadian Pharmacists Journal, 2008, 141, 33-38.	0.8	4
232	Responsiveness of Health State Utility Values in Knee Osteoarthritis. Journal of Rheumatology, 2013, 40, 2075-2082.	2.0	3
233	Health State Utilities and Disease Duration in Systemic Sclerosis: Is There an Association?. Journal of Rheumatology, 2016, 43, 1832-1837.	2.0	3
234	Validation of the Body Concealment Scale for Scleroderma (BCSS): Replication in the Scleroderma Patient-centered Intervention Network (SPIN) Cohort. Body Image, 2017, 20, 99-106.	4.3	3

#	Article	IF	CITATIONS
235	Assessment of inhaler technique among fourth-year pharmacy students: Implications for the use of entrustable professional activities. Currents in Pharmacy Teaching and Learning, 2020, 12, 281-286.	1.0	3
236	Evaluating New Zealanders' Values for Drug Coverage Decision Making: Trade-Offs between Treatments for Rare and Common Conditions. Pharmacoeconomics, 2021, 39, 109-119.	3.3	3
237	Examining non-medical prescribing trends in New Zealand: 2016–2020. BMC Health Services Research, 2021, 21, 418.	2.2	3
238	Identifying New Zealand Public Preferences for Pharmacist Prescribers in Primary Care: A Discrete Choice Experiment. Patient, 2022, 15, 77-92.	2.7	3
239	Comment: cost of rhDNase in cystic fibrosis. Annals of Pharmacotherapy, 1995, 29, 1050-1051.	1.9	2
240	Influence of Standardized Orders on Postoperative Nausea and Vomiting after Gynecologic Surgery. Annals of Pharmacotherapy, 2002, 36, 210-217.	1.9	2
241	In Reply: Antibiotic Use During the First Year of Life and Asthma. Chest, 2006, 130, 1624-1625.	0.8	2
242	Community pharmacist surveillance of hypertension in pregnancy. Canadian Pharmacists Journal, 2014, 147, 307-315.	0.8	2
243	Opinions and preferences of British Columbia pharmacists and physicians on medication management services. Canadian Pharmacists Journal, 2017, 150, 42-51.	0.8	2
244	What Are the Preferences of Patients With Rheumatoid Arthritis for Treatment Modification? A Scoping Review. Patient, 2021, 14, 505-532.	2.7	2
245	Impact of removing prescription charges on health outcomes: protocol for a randomised controlled trial. BMJ Open, 2021, 11, e049261.	1.9	2
246	Prevalence of joint-specific osteoarthritis and joint pain in British Columbia, Canada. Rheumatology International, 2021, , 1.	3.0	2
247	Using Best-Worst Choice Methodology in a Survey of Pharmacists Regarding Pharmacy Practice Skills Teaching. American Journal of Pharmaceutical Education, 2020, 84, 848015.	2.1	2
248	Knee osteoarthritis and the knowledgeable, trustworthy pharmacist: Patient and pharmacist perceptions of community pharmacyâ€based education and support. Musculoskeletal Care, 2023, 21, 3-15.	1.4	2
249	Outpatient Intravenous Antibiotic Therapy: The Vancouver Hospital experience. Canadian Journal of Infectious Diseases & Medical Microbiology, 2000, 11, 11A-14A.	0.3	1
250	Evolution of Clinical Pharmacy in the Practice of Rheumatology. Annals of Pharmacotherapy, 2007, 41, 1705-1707.	1.9	1
251	Letter to the Editor. Vaccine, 2008, 26, 5244.	3.8	1

Use Of Antibiotics Delays Diagnosis Of Tuberculosis. , 2010, , .

#	Article	IF	CITATIONS
253	The "Lost NNT―can be used to represent uncertainty surrounding number needed to treat. Journal of Clinical Epidemiology, 2012, 65, 863-868.	5.0	1
254	Cost–effectiveness of abatacept for moderate-to-severe rheumatoid arthritis. Expert Review of Pharmacoeconomics and Outcomes Research, 2014, 14, 9-18.	1.4	1
255	Determinants Of Quality Of Life In Newly Diagnosed Hiv Infected Patients In Kenya. Value in Health, 2014, 17, A280.	0.3	1
256	How do parents and providers trade-off between disability and survival? Preferences in the treatment of pediatric medulloblastoma. Patient Preference and Adherence, 2018, Volume 12, 2103-2110.	1.8	1
257	Identifying perceptions and themed learning outcomes between pharmacy and dentistry students through interprofessional education and collaboration in the dental clinic. Currents in Pharmacy Teaching and Learning, 2021, 13, 843-847.	1.0	1
258	Ampicillin-Induced Maculopapular versus Urticarial Rash. Annals of Pharmacotherapy, 1996, 30, 401-402.	1.9	0
259	Tracking and reporting drug expenditures. American Journal of Health-System Pharmacy, 1997, 54, 2302-2306.	1.0	0
260	Improving rheumatoid arthritis outcomes: How do we get there?. American Journal of Health-System Pharmacy, 2006, 63, S42-S44.	1.0	0
261	Self-managed oral anticoagulation therapy. Cmaj, 2007, 176, 813-814.	2.0	0
262	Economic evaluations of anticoagulants for the prophylaxis of venous thromboembolism following major trauma. Expert Review of Pharmacoeconomics and Outcomes Research, 2007, 7, 403-413.	1.4	0
263	Comparison of pregnancy rates after two hormonal emergency contraceptives. Contraception, 2011, 84, 333-334.	1.5	0
264	Safety Of Long-Acting Beta Agonists (LABA) With Or Without Inhaled Corticosteroids In Asthma. , 2012, , .		0
265	Authors' Response to "Comparative Effectiveness and Personalized Medicine―by Dr. J.C. Hornberger. Value in Health, 2013, 16, 697.	0.3	0
266	Avoiding immortal time bias in observational studies. European Respiratory Journal, 2020, 55, 1902494.	6.7	0
267	Are professional pharmacy services being offered for free in pharmacies? A feasibility study exploring the use of a time motion study in New Zealand. Pharmacy Practice, 2021, 19, 2422.	1.5	0
268	The Effect of Smartphone Interventions on Patients With Chronic Obstructive Pulmonary Disease Exacerbations: Systematic Review and Meta-Analysis. Iproceedings, 2017, 3, e6.	0.1	0
269	The challenge of making cost-effective asthma therapy available. International Journal of Tuberculosis and Lung Disease, 2009, 13, 545.	1.2	0